Cargando…
Refractory thyroid carcinoma: which systemic treatment to use?
The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers wi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788129/ https://www.ncbi.nlm.nih.gov/pubmed/29399055 http://dx.doi.org/10.1177/1758834017752853 |
_version_ | 1783296056758370304 |
---|---|
author | Faugeras, Laurence Pirson, Anne-Sophie Donckier, Julian Michel, Luc Lemaire, Julien Vandervorst, Sebastien D’Hondt, Lionel |
author_facet | Faugeras, Laurence Pirson, Anne-Sophie Donckier, Julian Michel, Luc Lemaire, Julien Vandervorst, Sebastien D’Hondt, Lionel |
author_sort | Faugeras, Laurence |
collection | PubMed |
description | The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy. |
format | Online Article Text |
id | pubmed-5788129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-57881292018-02-02 Refractory thyroid carcinoma: which systemic treatment to use? Faugeras, Laurence Pirson, Anne-Sophie Donckier, Julian Michel, Luc Lemaire, Julien Vandervorst, Sebastien D’Hondt, Lionel Ther Adv Med Oncol Review The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy. SAGE Publications 2018-01-23 /pmc/articles/PMC5788129/ /pubmed/29399055 http://dx.doi.org/10.1177/1758834017752853 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Faugeras, Laurence Pirson, Anne-Sophie Donckier, Julian Michel, Luc Lemaire, Julien Vandervorst, Sebastien D’Hondt, Lionel Refractory thyroid carcinoma: which systemic treatment to use? |
title | Refractory thyroid carcinoma: which systemic treatment to use? |
title_full | Refractory thyroid carcinoma: which systemic treatment to use? |
title_fullStr | Refractory thyroid carcinoma: which systemic treatment to use? |
title_full_unstemmed | Refractory thyroid carcinoma: which systemic treatment to use? |
title_short | Refractory thyroid carcinoma: which systemic treatment to use? |
title_sort | refractory thyroid carcinoma: which systemic treatment to use? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788129/ https://www.ncbi.nlm.nih.gov/pubmed/29399055 http://dx.doi.org/10.1177/1758834017752853 |
work_keys_str_mv | AT faugeraslaurence refractorythyroidcarcinomawhichsystemictreatmenttouse AT pirsonannesophie refractorythyroidcarcinomawhichsystemictreatmenttouse AT donckierjulian refractorythyroidcarcinomawhichsystemictreatmenttouse AT michelluc refractorythyroidcarcinomawhichsystemictreatmenttouse AT lemairejulien refractorythyroidcarcinomawhichsystemictreatmenttouse AT vandervorstsebastien refractorythyroidcarcinomawhichsystemictreatmenttouse AT dhondtlionel refractorythyroidcarcinomawhichsystemictreatmenttouse |